Current Controversies Surrounding PSA Screening
Release Date: December 2012
Expiration Date: December 2013
Estimated time to complete the educational activity: 1 hour
This activity is jointly sponsored by Medical Education Resources and Haymarket Medical Education.
Statement of Need: Moving forward with PSA screening mandates careful selection of those men most likely to derive benefit. It is hoped that selective screening, selective biopsy, and selective therapy will further decrease the morbidity associated with screening.
Target Audience: This activity has been designed to meet the educational needs of urologists and allied healthcare clinicians involved in screening patients for prostate cancer.
Educational Objectives: After completing the activity, the participant should be better able to:
- Review recent randomized trials and assess the benefits of PSA screening.
- Evaluate additional advantages and disadvantages of PSA screening.
Accreditation Statement:This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Medical Education Resources (MER) and Haymarket Medical Education. MER is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation: Medical Education Resources designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Conflicts of Interest: Medical Education Resources ensures balance, independence, objectivity, and scientific rigor in all our educational programs. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure all scientific research referred to, reported, or used in a CME activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing its learners with high-quality CME activities that promote improvements or quality in health care and not a commercial interest.
The faculty reported the following financial relationships with commercial interests whose products or services may be mentioned in this CME activity:
|Name of Faculty||Reported Financial Relationship|
|Gurdarshan S. Sandhu, MD||No financial relationships to disclose|
|Gerald L. Andriole, MD||Grants/Research Support: NIH, NIDDK, Johnson & Johnson, Medivation, Wilex. Consulting Fees: Amarex LLC, Amgen, Augmenix, Bayer, Bristol Myers Squibb, Cambridge Endosciences, Caris, GlaxoSmithKline, Janssen Biotech, Myriad Genetics, Steba Biotech, Ortho-Clinical Diagnostics, Viking Medical. Ownership Interest/Shareholder: Envisioneering Medical.|
The content managers, Jody A. Charnow and Marina Galanakis, of Haymarket Medical Education, and Julie Johnson, PharmD, of Medical Education Resources, have disclosed that they have no relevant financial relationships or conflicts of interest.
Method of Participation: There are no fees for participating in and receiving CME credit for this activity. During the period December 2012 through December 2013, participants must: 1) read the learning objectives and faculty disclosures, 2) study the educational activity, 3) complete the posttest and submit it online. Physicians may register at www.myCME.com/renalandurologynews, and 4) complete the evaluation form online.
A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed post-test with a score of 70% or better.